Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma
1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene ciloleucel (axi-cel) showed improvement in event-free survival compared ...